Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Enters $500M Credit Facility

NEW YORK – PerkinElmer has entered into a $500 million credit facility to pay, in part, its $5.25 billion acquisition of BioLegend, the Waltham, Massachusetts-based company said in a document filed with the US Securities and Exchange Commission on Thursday.

PerkinElmer entered into the unsecured delayed draw term loan credit facility on Aug. 11 with Bank of America as administrative agent. Other lenders include Goldman Sachs, JP Morgan Chase, and Wells Fargo, PerkinElmer said in the SEC document. The credit facility provides for a $500 million committed term loan to fund, in part, PerkinElmer's buy of BioLegend, to refinance certain indebtedness of BioLegend, and to pay fees and expenses associated with the acquisition and its financing.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.